tbuckley/cabot-search huggingface dataset:
Prospective Study of<i>CRMP4</i>Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases
Authors: Xin Gao, Liao-Yuan Li, Jörg Rassler, Jun Pang, Ming-Kun Chen, Wei-Peng Liu, Zheng Chen, Shan-Cheng Ren, Fang-Jian Zhou, Ke-Ji Xie, Xing Zhou, Hui-Jun Qian, Xian-Zhong Bai, Jiu-Min Liu, Jiang-Gen Yang, Dan He, Chun-Kui Shao, Zu-Lan Su, Jing Wang, Jian-Guang Qiu, Li Ling
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: For patients with prostate cancer (PCa), the presence of pelvic lymph node metastasis (LNM) is a strong predictor of poor outcome. However, the approaches with promising sensitivity and specificity to detect LNM are still lacking. We investigated the value of collapsin response mediator protein 4 (CRMP4) promoter methylation in biopsies as a predictor for LNM. Methods:CRMP4 promoter methylation at two previously identified CpG sites was determined in 80 case-matched biopsy samples (the training set) using bisulfite pyrosequencing. The predictive cutoff value was independently validated using cohort I of 339 PCa patients (Southern China) and cohort II of 328 case patients (Germany, across China). Mann-Whitney U test, the receiver operating characteristic curve, McNemar's test, and logistic regression were used to assess data. All statistical tests were two-sided. Results: In the training set, CRMP4 promoter methylation (≥15.0% methylated) was statistically significantly associated with LNM (P < .001). Successful validations were achieved in both cohorts I and II (sensitivity = 92.3%, 95% confidence interval [CI] = 79.3 to 97.9, and sensitivity = 92.2%, 95% CI = 81.1 to 97.8, respectively; specificity = 92.7%, 95% CI = 80.2 to 99.1, and specificity = 91.3%, 95% CI = 87.4 to 94.4, respectively). The sensitivity of CRMP4 promoter methylation is superior to conventional MRI (cohort I: 92.3% vs 26.2%, P < .001; cohort II: 92.2% vs 33.3%, P < .001). CRMP4 promoter methylation is an independent predictor of LNM (cohort I: hazard ratio [HR] = 8.35, 95% CI = 5.64 to 12.35, P < .001; cohort II: HR = 12.46, 95% CI = 5.82 to 26.70, P < .001) in a multivariable analysis model. Conclusion:CRMP4 promoter methylation in diagnostic biopsies could be a robust biomarker for LNM in PCa.
Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma
Authors: D. Maximous, M. E. Abdel-Wanis, M. A. Aboziada, M. I. El-Sayed, A. A. Abd-Elsayed
Journal: Journal of Clinical Oncology (2009)

e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis. Because surgical resection is often contraindicated by vascular invasion, this disease has a dismal prognosis. The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients’ unresectable pancreatic cancer. Aim of the work: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed. Methods: 25 patients were treated by preoperative gemcitabine based chemo-radiotherapy. Approximately 6 weeks after completion of chemo radiation, evaluation was performed regarding tumour response and resectability. Pancreatico-duodenectomy was done for operable patients with surgical reconstruction. Results: Patients who achieved complete remission (CR) were 2 out of 25 patients while those achieved partial remission (PR) were 11 out of 25, 6 of them were considered operable. Thus Pancreatico- duodenectomy was done for 8 patients with surgical reconstruction. The postoperative 30 day mortality occurred only in one patient. The postoperative morbidity occurred in the form of minor biliary leakage occurred only in 1 patient &amp; leakage from gastrointestinal anaestomosis in 1 patient. Out of 8 patients who underwent radical surgical resection, only one patient developed local recurrence and simultaneous liver metastasis during the follow up period. The median survival was 12 months. Conclusions: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity. No significant financial relationships to disclose.
Long-term visual prognosis of choroidal neovascularization in high myopia
Authors: Takeshi Yoshida, Kyoko Ohno-Matsui, Yoshiteru Ohtake, Takayuki Takashima, Soh Futagami, Takayuki Baba, Kenjiro Yasuzumi, Takashi Tokoro, Manabu Mochizuki
Journal: Ophthalmology (2002)
Abstract 12750: Ascorbate Prevents Hypertension, Proteinuria and Concentric Hypertrophy by Balancing the Nitroso-redox System in a Model of Preeclampsia, the S-nitrosoglutathione Reductase (gsnor) Deficient Mice
Authors: Shathiyah Kulandavelu, Raul A Dulce, Rosemeire K Takeuchi, Wayne Balkan, Joshua M Hare
Journal: Circulation (2016)

Introduction: Preeclampsia (PE), a leading cause of maternal and fetal mortality and morbidity, is characterized by increased levels of reactive oxygen species (ROS) and S-nitrosylated protein, and decreased levels of the antioxidant, ascorbate (Asc). Mice lacking S-nitrosoglutathione reductase (GSNOR –/– ), a denitrosylase that regulates protein S-nitrosylation, exhibit a PE-like phenotype including maternal hypertension, proteinuria, cardiac concentric hypertrophy and impaired placental vascularization. We hypothesize that the PE-like phenotype is mediated by nitroso-redox imbalance and nitrosative stress and can be rescued by ascorbate treatment. Methods: Pregnant GSNOR –/– and control (WT) mice (n=5-7) were provided drinking water ± Asc beginning on day 0.5 of gestation (E0.5). We determined blood pressure using a Millar catheter, relative wall thickness by echocardiography, and placental vascularization by isolectin staining. Cardiomyocytes (CM) were isolated at late stage pregnancy (E17.5) and levels of ROS (2’7’-dichlorofluorescein), nitric oxide (NO, diaminofluorescin) and peroxynitrite (dihydrorhodamine 123) were determined by fluorescence (ΔF/F 0 ). Results: CMs isolated from pregnant GSNOR –/– hearts, exhibited elevated levels of ROS (2.48±0.39 vs. 1.58±0.18 in WT, P&lt;0.05), free nitric oxide (6.65±0.43 vs. 5.59±0.26 in WT, P&lt;0.05) and peroxynitrite (0.75±0.04 vs. 0.39±0.03 in WT, P&lt;0.05). These increases were prevented with Asc treatment (P&lt;0.01), which completely rescued the PE phenotype in GSNOR –/– mothers, including hypertension (105±2 mmHg vs. 95± mmHg in Asc-treated, P&lt;0.05), proteinuria (P&lt;0.05) and relative wall thickness (0.56±0.04 vs. 0.45±0.03 in Asc-treated (P&lt;0.05). Placental vascularization was also significantly improved with Asc treatment in GSNOR –/– mothers. Asc had no effect on these parameters in WT mice. Conclusions: Our findings indicate that nitroso-redox imbalance and nitrosative stress contribute to PE in mice. Asc treatment balanced the nitroso-redox system and rescued the pathological phenotypes in GSNOR –/– mice, suggesting that it can be used therapeutically to treat or prevent preeclampsia.
Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection
Authors: Radek Plachy, Lenka Zejskova, Radek Cmejla, David Warren Hardekopf, Tereza Jancuskova, Lucie Krutilkova, Michal Karas, Vladimir Koza, Jan Vydra, Pavel Zak, Lukas Smolej, Sona Pekova
Journal: Blood (2011)
Prevention of Pediatric Abusive Head Trauma
Authors: John M. Leventhal, Andrea G. Asnes, Kirsten Bechtel
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
The Host Response in Patients with Sepsis Developing Intensive Care Unit–acquired Secondary Infections
Authors: Lonneke A. van Vught, Maryse A. Wiewel, Arie J. Hoogendijk, Jos F. Frencken, Brendon P. Scicluna, Peter M. C. Klein Klouwenberg, Aeilko H. Zwinderman, Rene Lutter, Janneke Horn, Marcus J. Schultz, Marc M. J. Bonten, Olaf L. Cremer, Tom van der Poll
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Sepsis can be complicated by secondary infections. We explored the possibility that patients with sepsis developing a secondary infection while in the intensive care unit (ICU) display sustained inflammatory, vascular, and procoagulant responses.Objectives: To compare systemic proinflammatory host responses in patients with sepsis who acquire a new infection with those who do not.Methods: Consecutive patients with sepsis with a length of ICU stay greater than 48 hours were prospectively analyzed for the development of ICU-acquired infections. Twenty host response biomarkers reflective of key pathways implicated in sepsis pathogenesis were measured during the first 4 days after ICU admission and at the day of an ICU-acquired infection or noninfectious complication.Measurements and Main Results: Of 1,237 admissions for sepsis (1,089 patients), 178 (14.4%) admissions were complicated by ICU-acquired infections (at Day 10 [6–13], median with interquartile range). Patients who developed a secondary infection showed higher disease severity scores and higher mortality up to 1 year than those who did not. Analyses of biomarkers in patients who later went on to develop secondary infections revealed a more dysregulated host response during the first 4 days after admission, as reflected by enhanced inflammation, stronger endothelial cell activation, a more disturbed vascular integrity, and evidence for enhanced coagulation activation. Host response reactions were similar at the time of ICU-acquired infectious or noninfectious complications.Conclusions: Patients with sepsis who developed an ICU-acquired infection showed a more dysregulated proinflammatory and vascular host response during the first 4 days of ICU admission than those who did not develop a secondary infection.
The HMGA1a-STAT3 axis: an “Achilles Heel” for Hematopoietic Malignancies Overexpressing HMGA1a?
Authors: Linda Resar, Joelle Hillion, Surajit Dhara, Takita Felder Sumter, Mita Mukherjee, Francescopaolo Di Cello, Amy Belton, James Turkson, Souyma Jaganathan, Linzhao Cheng, Zhaohui Ye, Yingwei Lin, Peter D. Aplan, Richard Jove, Jeanne Kowalski, Kelsey Wertzler, Ray Reeves, Ossama Elbahlouh, Raka Bhattacharya
Journal: Blood (2008)
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study
Authors: Motoi Suzuki, Bhim Gopal Dhoubhadel, Tomoko Ishifuji, Michio Yasunami, Makito Yaegashi, Norichika Asoh, Masayuki Ishida, Sugihiro Hamaguchi, Masahiro Aoshima, Koya Ariyoshi, Konosuke Morimoto
Journal: The Lancet Infectious Diseases (2017)
Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage
Authors: Aniko Szabo, Mathijs A. Sanders, Carla Exalto, Jasper E. Koenders, Patricia G. Hoogeveen, Anita M. Schelen, Willemijn van den Ancker, Arjan A. van de Loosdrecht, Bob Lowenberg, Vincent H.J. van der Velden, Jan J. Cornelissen, Peter J.M. Valk, Anita W. Rijneveld
Journal: Blood (2014)
New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles
Authors: Gabriele Pozzato, Nelly Mezzaroba, Sonia Zorzet, Erika Secco, Stefania Biffi, Claudio Tripodo, Marco Calvaruso, Luis Nuñez, Rubens Spretz, Gustavo Larsen, Sandra Noriega, Chiara Garrovo, Gustavo Marin, Edoardo Mansilla, Paolo Macor
Journal: Blood (2012)
Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.
Authors: Fabian Zohren, Ingmar Bruns, Juergen Barth, Sabrina Pechtel, Roland Fenk, Thomas Schroeder, Akos G. Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Gerhard Heil, Norbert Niederle, Christoph Losem, Manfred Welslau, Ulrich Germing, Ralf Kronenwett, Rainer Haas, Mathias J Rummel, Guido Kobbe
Journal: Blood (2009)
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Authors: Simon Yona, Ki-Wook Kim, Yochai Wolf, Alexander Mildner, Diana Varol, Michal Breker, Dalit Strauss-Ayali, Sergey Viukov, Martin Guilliams, Alexander Misharin, David A. Hume, Harris Perlman, Bernard Malissen, Elazar Zelzer, Steffen Jung
Journal: Immunity (2013)
Androgen receptor and HIF-1α interaction in prostate cancer.
Authors: Kelie M Reece, Sarah M Troutman, Heather M Pressler, Stephen T Pisle, William Douglas Figg
Journal: Journal of Clinical Oncology (2012)

197 Background: Prostate cancer is the most common noncutaneous cancer among men in the United States, and its progression is largely controlled by the androgen receptor (AR). Androgen deprivation therapy (ADT) is an initially effective treatment for prostate cancer, but most tumors eventually become castrate resistant. Tumor hypoxia also appears to be associated with a poor prognosis in prostate cancer. HIF-1a regulates the transcription of genes that allow tumor survival and growth in low oxygen conditions. Our laboratory has data showing that in response to castration and anti-androgen therapy in mice, there was a strong transcriptional relationship between HIF-1a and AR, as measured by quantitative RT-PCR, suggesting an interaction between the two proteins. Thus, the purpose of this study was to determine if there is a molecular interaction between HIF-1a and AR in prostate cancer cells. Methods: We used Western blot analysis to examine the expression levels of HIF-1a and AR in LNCaP prostate cancer cells to determine if they are upregulated together at the protein level. Four experimental conditions were tested: control (no treatment), DHT for induction of AR expression, CoCl2 for induction of HIF-1a, and a combination treatment of DHT and CoCl2. Immunoprecipitation experiments were carried out to determine if there is an association between HIF-1a and AR. In addition, cells were fractionated into nuclear and cellular cells extracts, followed by Western blot analysis to determine where in the cells this interaction occurs. Results: Western blot analysis of cell lysates showed synergistic upregulation of both HIF-1a and AR expression only under combined CoCl2 and DHT treatment conditions. In addition, immunoprecipitation experiments showed that HIF-1a and AR exist in a complex with one another, and fractionation experiments indicated this complex occurs in the nucleus. Conclusions: Our results demonstrate that HIF-1a and AR associate with one another in cells. Binding assays are in progress to determine the nature of this interaction. In addition, we are examining the cellular consequences of this protein interaction, as it is possible that upregulation of HIF-1a in response to low androgen contributes to the development of tumor resistance to ADT.
Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients
Authors: Ryotaro Nakamura, Corinna La Rosa, Jeff Longmate, Margaret O'Donnell, Ji-Lian Cai, Len Farol, Amandeep Salhotra, David S Snyder, Jennifer Drake, Cynthia Slape, James Merson, John A Zaia, Stephen J. Forman, Don J. Diamond
Journal: Blood (2014)
Analysis of Methylation Status of ZAR1, GATA4, CDH22, SOX3, SLC16A5, PFN2, EHD3 and TBPL1 in Hematological Malignancies
Authors: Yujin Kobayashi, Yoshihiro Hatta, Jin Takeuchi, Kyoko Fujiwara, Yui Shinojima, Hiroyuki Kawashima, Jun Igarashi, Hiroki Nagase
Journal: Blood (2011)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Authors: Ian Smith, Denise Yardley, Howard A. Burris, Richard De Boer, Dino Amadori, Kristi McIntyre, Bent Ejlertsen, Michael Gnant, Walter Jonat, Kathleen I. Pritchard, Mitch Dowsett, Lowell Hart, Susan Poggio, Lisa Comarella, Herve Salomon, Barbara Wamil, Joyce O’Shaughnessy
Journal: Journal of Clinical Oncology (2017)

Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.
Th1 Polarization of Cytokine and Cytokine Receptor Polymorphisms Affect the Susceptibility and Severity of ITP
Authors: Noriyuki Takahashi, Takayuki Saitoh, Nanami Gotoh, Kei Kimura, Yuko Kuroda, Kie Nagai, Tomomi Nagashima, Tetsuhiro Kasamatsu, Yusuke Minato, Hiroaki Shimizu, Takuma Ishizaki, Akihiko Yokohama, Makiko Takizawa, Hiromi Koiso, Takeki Mitsui, Norifumi Tsukamoto, Hiroshi Handa, Hirokazu Murakami
Journal: Blood (2015)
Junctional Adhesion Molecule-A/ F11 Receptor (JAM-A/ F11R) Expression in Multiple Myeloma (MM): a Candidate Biomarker of Aggressive Disease.
Authors: Bani M Azari, Marc J. Braunstein, H. Uwe Kluppelberg, Sadeaqua S Scott, Eric LP Smith, Jonathan D. Marmur, Anna Babinska, Olcay Batuman
Journal: Blood (2009)
Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society
Authors: A. Lallas, Z. Apalla, D. Ioannides, E. Lazaridou, A. Kyrgidis, P. Broganelli, R. Alfano, I. Zalaudek, G. Argenziano, Renato Bakos, Andreas Blum, Ralph Braun, Horacio Cabo, Allan Halpern, Rainer Hofmann‐Wellenhof, Harald Kittler, Josep Malvehy, Ashfaq Marghoob, Scott Menzies, Elvira Moscarella, John Paoli, Giovanni Pellacani, Susana Puig, Harold Rabinovitz, Alon Scope, Peter Soyer, Wilhelm Stolz, Masaru Tanaka, Luc Thomas, Philipp Tschandl
Journal: British Journal of Dermatology (2017)

Spitzoid lesions represent a challenging and controversial group of tumours, in terms of clinical recognition, biological behaviour and management strategies. Although Spitz naevi are considered benign tumours, their clinical and dermoscopic morphological overlap with spitzoid melanoma renders the management of spitzoid lesions particularly difficult. The controversy deepens because of the existence of tumours that cannot be safely histopathologically diagnosed as naevi or melanomas (atypical Spitz tumours). The dual objective of the present study was to provide an updated classification on dermoscopy of Spitz naevi, and management recommendations of spitzoid‐looking lesions based on a consensus among experts in the field. After a detailed search of the literature for eligible studies, a data synthesis was performed from 15 studies on dermoscopy of Spitz naevi. Dermoscopically, Spitz naevi are typified by three main patterns: starburst pattern (51%), a pattern of regularly distributed dotted vessels (19%) and globular pattern with reticular depigmentation (17%). A consensus‐based algorithm for the management of spitzoid lesions is proposed. According to it, dermoscopically asymmetric lesions with spitzoid features (both flat/raised and nodular) should be excised to rule out melanoma. Dermoscopically symmetric spitzoid nodules should also be excised or closely monitored, irrespective of age, to rule out atypical Spitz tumours. Dermoscopically symmetric, flat spitzoid lesions should be managed according to the age of the patient. Finally, the histopathological diagnosis of atypical Spitz tumour should warrant wide excision but not a sentinel lymph‐node biopsy.
Mouse Models of Human Mantle Cell Lymphoma for the Study of Disease Biology and for Pre-Clinical Assessment of Experimental Treatment Approaches.
Authors: Pavel Klener, Magdalena Klanova, Tomas Soukup, Jan Molinsky, Jan Zivny, Marek Trneny, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman, Emanuel Necas
Journal: Blood (2012)
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Authors: Bo Xiao, Zhigang Xu, Emilie Viennois, Yuchen Zhang, Zhan Zhang, Mingzhen Zhang, Moon Kwon Han, Yuejun Kang, Didier Merlin
Journal: Molecular Therapy (2017)

Overcoming adverse effects and selectively delivering drug to target cells are two major challenges in the treatment of ulcerative colitis (UC). Lysine-proline-valine (KPV), a naturally occurring tripeptide, has been shown to attenuate the inflammatory responses of colonic cells. Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs). The resultant HA-KPV-NPs had a desirable particle size (∼272.3 nm) and a slightly negative zeta potential (∼-5.3 mV). These NPs successfully mediated the targeted delivery of KPV to key UC therapy-related cells (colonic epithelial cells and macrophages). In addition, these KPV-loaded NPs appear to be nontoxic and biocompatible with intestinal cells. Intriguingly, we found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation. Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system. These results collectively demonstrate that our HA-KPV-NP/hydrogel system has the capacity to release HA-KPV-NPs in the colonic lumen and that these NPs subsequently penetrate into colitis tissues and enable KPV to be internalized into target cells, thereby alleviating UC.